Hypericin is under clinical development by Soligenix and currently in Pre-Registration for Cutaneous T-Cell Lymphoma. According to GlobalData, Pre-Registration drugs for Cutaneous T-Cell Lymphoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Hypericin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hypericin overview
Hypericin (SGX-301, HBP-347) is under development for the treatment of mild-moderate psoriasis and cutaneous T-cell lymphoma such as Folliculotropic mycosis fungoides (FMF) and plaque psoriasis. It is a photodynamic therapy utilizing safe visible light for activation. The active ingredient of HBP-347, synthetic hypericin, is a photosensitizer which is topically applied to skin lesions and activated by fluorescent light. Hypericin inactivates Hsp90 via ubiquitinylation of the chaperone. The drug candidate was also under development for the treatment of inflammatory bowel diseases, ocular diseases and glioblastoma as oral administration.
Soligenix overview
Soligenix is a late-stage biopharmaceutical company which focuses on the development and commercialization of products for the treatment of rare diseases and unmet medical needs. It develops specialized biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn’s disease, oral mucositis, mild to moderate psoriasis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation. The company has active development programs for RiVax, a ricin toxin vaccine; and SGX943 for infectious disease. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.
For a complete picture of Hypericin’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
